Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
J Heart Lung Transplant
; 19(7): 710-5, 2000 Jul.
Article
en En
| MEDLINE
| ID: mdl-10930822
BACKGROUND: Cardiac transplant patients are at increased risk of dyslipidemia, a known pathogenetic factor in chronic rejection. The aim of this study was to compare the efficacy and the safety of treatment with atorvastatin (AT) and treatment with pravastatin (PV) in a population of dyslipidemic transplant patients. METHODS: Thirty-nine transplant patients were randomized to receive a 4-month cycle of therapy with AT or PV, in a cross-over sequence. We analyzed the effects on their lipid profiles using Student t-test for paired data. RESULTS AND CONCLUSION: Atorvastatin was significantly more effective than PV in reducing total cholesterol (33% vs 21%, p < 0.001), LDL cholesterol (45% vs 30%, p = 0.001), and triglycerides (24% vs 7.7%, p < 0.001), at lower doses and with comparable tolerability and safety.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pirroles
/
Trasplante de Corazón
/
Pravastatina
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Ácidos Heptanoicos
/
Hiperlipidemias
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Heart Lung Transplant
Asunto de la revista:
CARDIOLOGIA
/
TRANSPLANTE
Año:
2000
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Estados Unidos